Medical Methods to Induce Abortion in the Second Trimester

Management of Unintended and Abnormal Pregnancy: Comprehensive Abortion Care

Volumn , Issue , 2009, Pages 178-192

  Kapp, Nathalie ^a   Hertzen, Helena Von ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Blockage of progesterone receptors and breakdown of maternal capillaries in decidua; Gemeprost and misoprostol common prostaglandin analogs for inducing abortion; Induction abortion termination of pregnancy by labor like contraction stimulation; Medical methods to induce abortion in second trimester; Mifepristone blocking receptors for progesterone and glucocorticosteroids; Prostaglandins inducing abortion

Indexed keywords

EID: 77950861343     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444313031.ch12     Document Type: Chapter

References (120)

1. Blumenthal PD, Castleman LD, Jain JK. (1999) Abortion by labor induction. In: Paul M, Lichtenberg ES, Borgotta L, Grimes DA, Stubblefield PG, eds. A Clinician's Guide to Medical and Surgical Abortion. Churchill Livingstone, New York, 1999.
2. Kaltreider NB, Goldsmith S, Margolis AJ. The impact of midtrimester abortion techniques on patients and staff. Am J Obstet Gynecol 1979; 135: 235-238.
3. Grimes DA, Smith MS, Witham AD. Mifepristone and misoprostol versus dilation and evacuation for midtrimester abortion:a pilot randomised controlled trial. BJOG 2004; 111: 148-153.
4. Shulman LP, Ling FW, Meyers CM, Shanklin DR, Simpson JL, Elias S. Dilation and evacuation for second-trimester genetic pregnancy termination. Obstet Gynecol 1990; 75: 1037-1040.
5. Partial-Birth Abortion Ban Act of 2003. 18 U.S.C. §1531 (2003).
6. World Health Organization. Safe Abortion: Technical and Policy Guidance for Health Systems. World Health Organization, Geneva, 2003.
7. Royal College of Obstetricians and Gynaecologists. The Care of Women Requesting Induced Abortion. Royal College of Obstetricians and Gynaecology Press, London, 2004.
8. Ashok PW, Templeton A, Wagaarachchi PT, Flett GM. Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. Contraception 2004; 69: 51-58.
9. Rose SB, Shand C, Simmons A. Mifepristone- and misoprostolinduced mid-trimester termination of pregnancy: a review of 272 cases. Aust N Z J Obstet Gynaecol 2006; 46: 479-485.
10. Sedgh G, Henshaw S, Singh S, Ahman E, Shah IH. Induced abortion: estimated rates and trends worldwide. Lancet 2007; 370: 1338-1345.
11. Gamble SB, Strauss LT, Parker WY et al. Abortion surveillance - United States, 2005. MMWR Surveill Summ 2008; 56: SS-13.
12. Socialstyrelsen [Online]. Stockholm: 2005. Aborter 2005 [cited 2009 Jan 2]. Available from: URL: http://www.socialstyrelsen. se/NR/rdonlyres/A15D144C-EE18-4CA0-B141-48EED8D6 F7B6/5496/Publ200506422.pdf
13. Guttmacher Institute [online]. Issues in Brief: The Limitations of U.S. Statistics on Abortion; 1997 [cited 2009 Jan 2]. Available from: URL: http://www.guttmacher.org/pubs/ib14. html
14. World Health Organization. Medical Methods for Termination of Pregnancy. World Health Organization, Geneva, 1997: 871.
15. Finer LB, Frohwirth LF, Dauphinee LA, Singh S, Moore AM. Timing of steps and reasons for delays in obtaining abortions in the United States. Contraception 2006; 74: 334-344.
16. Guilbert E, Marcoux S, Rioux JE. Factors associated with the obtaining of a second-trimester induced abortion. Can J Public Health 1994; 85: 402-406.
17. Jones RK, Darroch JE, Henshaw SK. Patterns in the socioeconomic characteristics of women obtaining abortions in 2000-2001. Perspect Sex Reprod Health 2002; 34: 226-235.
18. World Health Organization. Frequently Asked Questions about Medical Abortion. World Health Organization, Geneva, 2006.
19. Vogel D, Burkhardt T, Rentsch K et al. Misoprostol versus methylergometrine: pharmacokinetics in human milk. Am J Obstet Gynecol 2004; 191: 2168-2173.
20. Fiala C, Gemzell-Danielsson K. Review of medical abortion using mifepristone in combination with a prostaglandin analog. Contraception 2006; 74: 66-86.
21. Delvaux T, Nöstlinger C. Reproductive choice for women and men living with HIV: contraception, abortion, and fertility. Reprod Health Matters 2007; 15: 46-66.
22. Marcollet A, Goffinet F, Firtion G et al. Differences in postpartum morbidity in women who are infected with the human immunodeficiency virus after elective cesarean delivery, emergency cesarean delivery, or vaginal delivery. Am J Obstet Gynecol 2002; 186: 784-789.
23. Duarte G, Read JS, Gonin R et al. Mode of delivery and postpartum morbidity in Latin American and Caribbean countries among women who are infected with human immunodeficiency virus-1: the NICHD International Site Development Initiative (NISDI) Perinatal Study. Am J Obstet Gynecol 2006; 195:215-229.
24. Blanchard K, Clark S, Winikoff B, Gaines G, Kabani G, Shannon C. Misoprostol for women's health: a review. Obstet Gynecol 2002; 99: 316-332.
25. Bhattacharjee N, Ganguly RP, Saha SP. Misoprostol for termination of mid-trimester post-Caesarean pregnancy. Aust N Z J Obstet Gynaecol 2007; 47: 23-25.
26. Daponte A, Nzewenga G, Dimopoulos KD, Guidozzi F. The use of vaginal misoprostol for second-trimester pregnancy termination in women with previous single cesarean section. Contraception 2006; 74: 324-327.
27. Daskalakis GJ, Mesogitis SA, Papantoniou NE, Moulopoulos GG, Papapanagiotou AA, Antsaklis AJ. Misoprostol for second trimester pregnancy termination in women with prior caesarean section. BJOG 2005; 112: 97-99.
28. Marinoni E, Santoro M, Vitagliano MP, Patella A, Cosmi EV, Di Iorio R. Intravaginal gemeprost and second-trimester pregnancy termination in the scarred uterus. Int J Gynaecol Obstet 2007; 97: 35-39.
29. Mazouni C, Provensal M, Porcu G et al. Termination of pregnancy in patients with previous cesarean section. Contraception 2006; 73: 244-248.
30. Shammas AG, Momani MD. Misoprostol for termination of second trimester pregnancy in a scarred uterus. Saudi Med J 2006; 27: 1173-1176.
31. Bagga R, Chaudhary N, Kalra J. Rupture in an unscarred uterus during second trimester pregnancy termination with mifepristone and misoprostol. Int J Gynaecol Obstet 2004; 87: 42-43.
32. Malhotra N, Chanana C. Silent rupture of unscarred uterus: an unusual presentation at second trimester abortion. Arch Gynecol Obstet 2007; 275: 283-284.
33. Lähteenmäki P, Heikinheimo O, Croxatto H et al. Pharmacokinetics and metabolism of RU486. J Steroid Biochem 1987; 27:859-863.
34. Swahn ML, Bygdeman M. The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. Br J Obstet Gynaecol 1988; 95: 126-134.
35. Johannisson E, Oberholzer M, Swahn ML, Bygdeman M. Vascular changes in the human endometrium following the administration of the progesterone antagonist RU 486. Contraception 1989; 39: 103-117.
36. Smith SK, Kelly RW. The effect of the antiprogestins RU 486 and ZK 98734 on the synthesis and metabolism of prostaglandins F2 alpha and E2 in separated cells from early human decidua. J Clin Endocrinol Metab 1987; 65: 527-534.
37. Cheng L, Kelly RW, Thong KJ, Hume R, Baird DT. The effects of mifepristone (RU486) on prostaglandin dehydrogenase in decidual and chorionic tissue in early pregnancy. Hum Reprod 1993; 8: 705-709.
38. Bygdeman M, Swahn ML. Progesterone receptor blockage: effect on uterine contractility and early pregnancy. Contraception 1985; 32: 45-51.
39. Tang OS, Chan CC, Kan AS, Ho PC. A prospective randomized comparison of sublingual and oral misoprostol when combined with mifepristone for medical abortion at 12-20 weeks' gestation. Hum Reprod 2005; 20: 3062-3066.
40. Thong KJ, Baird DT. Induction of second trimester abortion with mifepristone and gemeprost. Br J Obstet Gynaecol 1993; 100: 758-761.
41. Webster D, Penney GC, Templeton A. A comparison of 600 and 200 mg mifepristone prior to second trimester abortion with the prostaglandin misoprostol. Br J Obstet Gynaecol 1996; 103:706-709.
42. el-Refaey H, Templeton A. Induction of abortion in the second trimester by a combination of misoprostol and mifepristone:a randomized comparison between two misoprostol regimens. Hum Reprod 1995; 10: 475-478.
43. Bartley J, Baird DT. A randomised study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. BJOG 2002; 109:1290-1294.
44. Heikinheimo O, Suhonen S, Haukkamaa M. One- and two-day mifepristone-misoprostol intervals are both effective in medical termination of second-trimester pregnancy. Reprod Biomed Online 2004; 8: 236-239.
45. Nilas L, Glavind-Kristensen M, Vejborg T, Knudsen UB. One- or two-day mifepristone-misoprostol interval for second trimester abortion. Acta Obstet Gynecol Scand 2007; 86: 1117-1121.
46. Gynuity Health Projects [Online]. New York: Gynuity Health Projects; 2007. Resources: medical abortion; 2007 [cited 2008 Aug 7]. Available from: URL:http://www.gynuity.org/pub b.html
47. Kapp N, Borgatta L, Stubblefield PG, Vragovic O, Moreno N. Mifepristone in midtrimester medical abortion: a randomized controlled trial. Obstet Gynecol 2007; 110: 1304-1310.
48. Goldberg AB, Greenberg MB, Darney PD. Misoprostol and pregnancy. N Engl J Med 2001; 344: 38-47.
49. Ngai SW, Tang OS, Ho PC. Randomized comparison of vaginal (200 microg every 3 h) and oral (400 microg every 3 h) misoprostol when combined with mifepristone in termination of second trimester pregnancy. Hum Reprod 2000; 15: 2205-2208.
50. Green J, Borgatta L, Sia M et al. Intervention rates for placental removal following induction abortion with misoprostol. Contraception 2007; 76: 310-313.
51. Ho PC, Ngai SW, Liu KL, Wong GC, Lee SW. Vaginal misoprostol compared with oral misoprostol in termination of secondtrimester pregnancy. Obstet Gynecol 1997; 90: 735-738.
52. Ashok PW, Templeton A. Nonsurgical mid-trimester termination of pregnancy: a review of 500 consecutive cases. Br J Obstet Gynaecol 1999; 106: 706-710.
53. Nigam A, Singh VK, Prakash A. Vaginal vs. oral misoprostol for mid-trimester abortion. Int J Gynaecol Obstet 2006; 92: 270-271.
54. Tang OS, Lau WN, Chan CC, Ho PC. A prospective randomised comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. BJOG 2004; 111: 1001-1005.
55. Ho PC, Blumenthal PD, Gemzell-Danielsson K, Gómez Ponce de León R, Mittal S, Tang OS. Misoprostol for the termination of pregnancy with a live fetus at 13 to 26 weeks. Int J Gynaecol Obstet 2007; 99: S178-S181.
56. Borgatta L, Chen AY, Vragovic O, Stubblefield PG, Magloire CA. A randomized clinical trial of the addition of laminaria to misoprostol and hypertonic saline for second-trimester induction abortion. Contraception 2005; 72: 358-361.
57. Pongsatha S, Tongsong T. Intravaginal misoprostol for pregnancy termination. Int J Gynaecol Obstet 2004; 87: 176-177.
58. Wong KS, Ngai CS, Wong AY, Tang LC, Ho PC. Vaginal misoprostol compared with vaginal gemeprost in termination of second trimester pregnancy. A randomized trial. Contraception 1998; 58: 207-210.
59. Wong KS, Ngai CS, Yeo EL, Tang LC, Ho PC. A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: a randomized comparative trial. Hum Reprod 2000; 15: 709-712.
60. Kapp N, Todd CS, Yadgarova KT et al. A randomized comparison of misoprostol to intrauterine instillation of hypertonic saline plus a prostaglandin F2alpha analogue for secondtrimester induction termination in Uzbekistan. Contraception 2007; 76: 461-466.
61. Bygdeman M. Comparison of prostaglandin and hypertonic saline for termination of pregnancy. Obstet Gynecol 1978; 52:424-429.
62. Karim SM, Ratnam SS. Termination of abnormal intrauterine pregnancies with intramuscular administration of dihomo 15 methyl prostaglandin F2 alpha. Br J Obstet Gynaecol 1976; 83:885-889.
63. Lalitkumar S, Bygdeman M, Gemzell-Danielsson K. Midtrimester induced abortion: a review. Human Reprod Update 2007; 13: 37-52.
64. Peyron R, Aubény E, Targosz V et al. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med 1993; 328: 1509-1513.
65. Ulmann A, Silvestre L, Chemama L et al. Medical termination of early pregnancy with mifepristone (RU 486) followed by a prostaglandin analogu. Study in 16,369 women. Acta Obstet Gynecol Scand 1992; 71: 278-283.
66. Andersen LF, Poulsen HK, Sørensen SS, Christensen BM, Sponland G, Skjeldestad FE. Termination of second trimester pregnancy with gemeprost vaginal pessaries and intra-amniotic PGF2 alpha. A comparative study. Eur J Obstet Gynecol Reprod Biol 1989; 31: 1-7.
67. Cameron IT, Baird DT. The use of 16,16-dimethyl-trans delta 2 prostaglandin E1 methyl ester (gemeprost) vaginal pessaries for the termination of pregnancy in the early second trimester. A comparison with extra-amniotic prostaglandin E2. Br J Obstet Gynaecol 1984; 91: 1136-1140.
68. Makhlouf AM, Al-Hussaini TK, Habib DM, Makarem MH. Second-trimester pregnancy termination: comparison of three different methods. J Obstet Gynaecol 2003; 23: 407-411.
69. Su LL, Biswas A, Choolani M, Kalaichelvan V, Singh K. A prospective, randomized comparison of vaginal misoprostol versus intra-amniotic prostaglandins for midtrimester termination of pregnancy. Am J Obstet Gynecol 2005; 193: 1410-1414.
70. Nor Azlin MI, Abdullah HS, Zainul Rashid MR, Jamil MA. Misoprostol (alone) in second trimester terminations of pregnancy:as effective as Gemeprost? J Obstet Gynaecol 2006; 26:546-549.
71. Nuutila M, Toivonen J, Ylikorkala O, Halmesmäki E. A comparison between two doses of intravaginal misoprostol and gemeprost for induction of second-trimester abortion. Obstet Gynecol 1997; 90: 896-900.
72. Dodd JM, Crowther CA. Misoprostol versus cervagem for the induction of labour to terminate pregnancy in the second and third trimester: a systematic review. Eur J Obstet Gynecol Reprod Biol 2006; 125: 3-8.
73. Neilson JP, Hickey M, Vasquez J. Medical treatment for early fetal death (less than 24 weeks). Cochrane Database Syst Rev 2006; 3: CD002253.
74. Gustavii B. Studies on accidental intravascular injection in extra-amniotic saline induced abortion and a method for reducing this risk. J Reprod Med 1972; 8: 70-74.
75. Toppozada M, Ismail AA. Intrauterine administration of drugs for termination of pregnancy in the second trimester. Baillieres Clin Obstet Gynaecol 1990; 4: 327-349.
76. Ingemanson CA. Legal abortion by extra-amniotic instillation of Rivanol in combination with rubber catheter insertion into the uterus after the twelfth week of pregnancy. Am J Obstet Gynecol 1973; 115: 211-215.
77. Berg C, Ludwig M, Sturm N, Diedrich K, Gembruch U, Geipel A. Intra-amniotic ethacridine lactate instillation versus vaginal PGE1 in second trimester termination of pregnancy. Eur J Obstet Gynecol Reprod Biol 2006; 126: 193-196.
78. Gardó S, Nagy M. Induction of second trimester abortion by intra-amniotic instillation of Rivanol (ethacridine) combined with oxytocin infusion. Arch Gynecol Obstet 1990; 247: 39-41.
79. Tien KH. Intra-amniotic injection of ethacridine for secondtrimester induction of labor. Obstet Gynecol 1983; 61: 733-736.
80. Allahbadia G. Comparative study of midtrimester termination of pregnancy using hypertonic saline, ethacridine lactate, prostaglandin analogue, and iodine-saline. J Indian Med Assoc 1992; 90: 237-239.
81. Herabutya Y, O-Prasertsawat P. Mid-trimester abortion using hypertonic saline or prostaglandin E2 gel: an analysis of efficacy and complications. J Med Assoc Thai 1994; 77: 148-152.
82. Binkin NJ, Schulz KF, Grimes DA, Cates W Jr. Ureaprostaglandin versus hypertonic saline for instillation abortion. Am J Obstet Gynecol 1983; 146: 947-952.
83. Nuthalapaty FS, Ramsey PS, Biggio JR, Owen J. High-dose vaginal misoprostol versus concentrated oxytocin plus lowdose vaginal misoprostol for midtrimester labor induction: a randomized trial. Am J Obstet Gynecol 2005; 193: 1065-1070.
84. Winkler CL, Gray SE, Hauth JC, Owen J, Tucker JM. Midsecond- trimester labor induction: concentrated oxytocin compared with prostaglandin E2 vaginal suppositories. Obstet Gynecol 1991; 77: 297-300.
85. Abramovici H, Bornstein J, Ben-David Y, Yishai D, Rofe A, Atad J. Double-balloon instillation device for second-trimester abortion. Outcome in 340 consecutive cases. J Reprod Med 1995; 40:56-62.
86. Toppozada MK, Shaala SA, Anwar MY, Haiba NA, Abdrabbo S, el-Absy HM. Termination of pregnancy with fetal death in the second and third trimesters-the double balloon versus extra-amniotic prostaglandin. Int J Gynaecol Obstet 1994; 45:269-273.
87. Drey EA, Thomas LJ, Benowitz NL, Goldschlager N, Darney PD. Safety of intra-amniotic digoxin administration before late second-trimester abortion by dilation and evacuation. Am J Obstet Gynecol 2000; 182: 1063-1066.
88. Isada NB, Pryde PG, Johnson MP, Hallak M, Blessed WB, Evans MI. Fetal intracardiac potassium chloride injection to avoid the hopeless resuscitation of an abnormal abortus: 1. Clinical issues. Obstet Gynecol 1992; 80: 296-299.
89. Hern WM, Zen C, Ferguson KA, Hart FV, Haseman MV. Outpatient abortion for fetal anomaly and fetal death from 15-34 menstrual weeks' gestation: techniques and clinical management. Obstet Gynecol 1993; 81: 301-306.
90. Elimian A, Verma U, Tejani N. Effect of causing fetal cardiac asystole on second-trimester abortion. Obstet Gynecol 1999; 94:139-141.
91. Atlas RO, Lemus J, Reed J III, Atkins D, Alger LS. Second trimester abortion using prostaglandin E2 suppositories with or without intracervical Laminaria japonica: a randomized study. Obstet Gynecol 1998; 92: 398-402.
92. Blumenthal PD. Prospective comparison of Dilapan and laminaria for pretreatment of the cervix in second-trimester induction abortion. Obstet Gynecol 1988; 72: 243-246.
93. Strauss JH, Wilson M, Caldwell D, Otterson W, Martin AO. Laminaria use in midtrimester abortions induced by intraamniotic prostaglandin F2alpha with urea and intravenous oxytocin. Am J Obstet Gynecol 1979; 134: 260-264.
94. Karim SM, Ratnam SS, Lim AL, Yeo KC, Choo HT. Termination of second trimester pregnancy with laminaria and intramuscular 16 phenoxy-omega-17, 18, 19, 20 tetranor PGE2methylsulfonylamide (sulprostone)-A randomized study. Prostaglandins 1982; 23: 257-263.
95. Papageorgiou I, Minaretzis D, Tsionou C, Michalas S. Late midtrimester medical pregnancy terminations: three different procedures with prostaglandin F2 alpha and laminaria tents. Prostaglandins 1991; 41: 487-493.
96. Stubblefield PG, Naftolin F, Frigoletto F, Ryan KJ. Laminaria augmentation of intra-amniotic PGF2 for midtrimester pregnancy termination. Prostaglandins 1975; 10: 413-422.
97. Surrago EJ, Robins J. Mid-trimester pregnancy termination by intravaginal administration of prostaglandin E2. Contraception 1982; 26: 285-294.
98. Jain JK, Mishell DR Jr. A comparison of misoprostol with and without laminaria tents for induction of second-trimester abortion. Am J Obstet Gynecol 1996; 175: 173-177.
99. Ho PC, Tsang SS, Ma HK. Reducing the induction to abortion interval in termination of second trimester pregnancies: a comparison of mifepristone with laminaria tent. Br J Obstet Gynaecol 1995; 102: 648-651.
100. Prairie BA, Lauria MR, Kapp N, MacKenzie T, Baker ER, George KE. Mifepristone versus laminaria: a randomized controlled trial of cervical ripening in midtrimester termination. Contraception 2007; 76: 383-388.
101. Thong KJ, Baird DT. A study of gemeprost alone, dilapan or mifepristone in combination with gemeprost for the termination of second trimester pregnancy. Contraception 1992; 46:11-17.
102. Schubert W, Cullberg G. Second trimester abortion by Rivanol with or without cervical dilatators. A randomized comparison. Acta Obstet Gynecol Scand 1987; 66: 549-550.
103. Berger GS, Kerenyi TD. Analysis of retained placenta associated with saline abortion: clinical considerations. Am J Obstet Gynecol 1974; 120: 484-488.
104. Kirz DS, Haag MK. Management of the third stage of labor in pregnancies terminated by prostaglandin E2. Am J Obstet Gynecol 1989; 160: 412-414.
105. Hamoda H, Ashok PW, Flett GM, Templeton A. A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13-20 weeks' gestation. Hum Reprod 2005; 20: 2348-2354.
106. Honkanen H, Piaggio G, Hertzen H et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. II: Side effects and women's perceptions. BJOG 2004; 111: 715-725.
107. Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med 1998; 338: 1241-1247.
108. Fiala C, Swahn ML, Stephansson O, Gemzell-Danielsson K. The effect of nonsteroidal antiinflammatory drugs on medical abortion with mifepristone and misoprostol at 13-22 weeks' gestation. Hum Reprod 2005; 20: 3072-3077.
109. Creinin MD, Shulman T. Effect of nonsteroidal antiinflammatory drugs on the action of misoprostol in a regimen for early abortion. Contraception 1997; 56: 165-168.
110. Li CF, Wong CY, Chan CP, Ho PC. A study of co-treatment of nonsteroidal antiinflammatory drugs (NSAIDs) with misoprostol for cervical priming before suction termination of first trimester pregnancy. Contraception 2003; 67: 101-105.
111. Westhoff C, Dasmahapatra R, Winikoff B, Clarke S. Predictors of analgesia use during supervised medical abortion. Contraception 2000; 61: 225-229.
112. Hamoda H, Ashok PW, Flett GM, Templeton A. Analgesia requirements and predictors of analgesia use for women undergoingmedical abortion up to 22 weeks of gestation. BJOG 2004; 111: 996-1000.
113. Wiebe E. Pain control in medical abortion. Int J Gynaecol Obstet 2001; 74: 275-280.
114. Burkman RT, Atienza MF, King TM, Burnett LS. The management of midtrimester abortion failures by vaginal evacuation. Obstet Gynecol 1977; 49: 233-236.
115. World Health Organization. Report of a Technical Consultation on Birth Spacing. World Health Organization, Geneva, 2005.
116. Boyd EF Jr, Halmstrom EG. Ovulation following therapeutic abortion. Am J Obstet Gynecol 1972; 113: 469-473.
117. World Health Organization Department of Reproductive Health and Research & Johns Hopkins Bloomberg School of Public Health Center for Communication Programs, INFO Project. Family Planning: A Global Handbook for Providers. CCP and WHO, Baltimore and Geneva, 2007.
118. Grimes D, Schulz K, Stanwood N. Immediate postabortal insertion of intrauterine devices. Cochrane Database Syst Rev 2004; 4:CD001777.
119. Nyoboe Andersen A, Damm P, Tabor A, Pedersen IM, Harring M. Prevention of breast pain and milk secretion with bromocriptine after second-trimester abortion. Acta Obstet Gynecol Scand 1990; 69: 238.
120. Talluri-Rao S, Baird TL. Information and Training Guide for Medical Abortion Counseling. Ipas, Chapel Hill, 2003.